Abstract
Measurements of the effect of NOAs are indicated in several situations: (a) patients with adverse events (i.e., thrombotic/hemorrhagic), particularly those who present with overdosage owing to excessive drug intake or decreased clearance; (b) patients undergoing surgical procedures for ensuring that no residual drug remains in the circulation; (c) patients requiring anticoagulation reversal because of life-threatening hemorrhage; (d) patients with renal insufficiency, who are likely to accumulate the drug in the circulation; (e) patients with liver failure, because NOAs are metabolized by the liver; (f) patients taking other drugs that might increase/decrease the effects of NOAs via drug- drug interactions. The choice of tests is based on such characteristics as availability, linearity of the dose- response curve, standardization, and responsiveness to increasing drug dosage. Practitioners need to be aware that NOAs can interfere with the measurement of common hemostasis parameters.
| Original language | English |
|---|---|
| Pages (from-to) | 353-362 |
| Number of pages | 10 |
| Journal | Clinical Chemistry |
| Volume | 59 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 2013 |
Fingerprint
ASJC Scopus subject areas
- Clinical Biochemistry
- Biochemistry, medical
Cite this
The laboratory and the new oral anticoagulants. / Tripodi, Armando.
In: Clinical Chemistry, Vol. 59, No. 2, 02.2013, p. 353-362.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The laboratory and the new oral anticoagulants
AU - Tripodi, Armando
PY - 2013/2
Y1 - 2013/2
N2 - Measurements of the effect of NOAs are indicated in several situations: (a) patients with adverse events (i.e., thrombotic/hemorrhagic), particularly those who present with overdosage owing to excessive drug intake or decreased clearance; (b) patients undergoing surgical procedures for ensuring that no residual drug remains in the circulation; (c) patients requiring anticoagulation reversal because of life-threatening hemorrhage; (d) patients with renal insufficiency, who are likely to accumulate the drug in the circulation; (e) patients with liver failure, because NOAs are metabolized by the liver; (f) patients taking other drugs that might increase/decrease the effects of NOAs via drug- drug interactions. The choice of tests is based on such characteristics as availability, linearity of the dose- response curve, standardization, and responsiveness to increasing drug dosage. Practitioners need to be aware that NOAs can interfere with the measurement of common hemostasis parameters.
AB - Measurements of the effect of NOAs are indicated in several situations: (a) patients with adverse events (i.e., thrombotic/hemorrhagic), particularly those who present with overdosage owing to excessive drug intake or decreased clearance; (b) patients undergoing surgical procedures for ensuring that no residual drug remains in the circulation; (c) patients requiring anticoagulation reversal because of life-threatening hemorrhage; (d) patients with renal insufficiency, who are likely to accumulate the drug in the circulation; (e) patients with liver failure, because NOAs are metabolized by the liver; (f) patients taking other drugs that might increase/decrease the effects of NOAs via drug- drug interactions. The choice of tests is based on such characteristics as availability, linearity of the dose- response curve, standardization, and responsiveness to increasing drug dosage. Practitioners need to be aware that NOAs can interfere with the measurement of common hemostasis parameters.
UR - http://www.scopus.com/inward/record.url?scp=84873114043&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84873114043&partnerID=8YFLogxK
U2 - 10.1373/clinchem.2012.189704
DO - 10.1373/clinchem.2012.189704
M3 - Article
C2 - 23043068
AN - SCOPUS:84873114043
VL - 59
SP - 353
EP - 362
JO - Clinical Chemistry
JF - Clinical Chemistry
SN - 0009-9147
IS - 2
ER -